PART I Overview We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on...
Q2 FY2026 — expected 2026-09-15
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | RPRX | discussed_in_filing Cybersecurity | |
| topic_mention | RPRX | discussed_in_filing Trusted Computing | |
| topic_mention | RPRX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | RPRX | discussed_in_filing Regulation | |
| topic_mention | RPRX | discussed_in_filing Healthcare & Bio | |
| topic_mention | RPRX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | RPRX | discussed_in_filing Cybersecurity | |
| topic_mention | RPRX | discussed_in_filing Trusted Computing | |
| topic_mention | RPRX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | RPRX | discussed_in_filing Regulation | |
| topic_mention | RPRX | discussed_in_filing Healthcare & Bio | |
| topic_mention | RPRX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | RPRX | discussed_in_filing Cybersecurity | |
| topic_mention | RPRX | discussed_in_filing Trusted Computing | |
| topic_mention | RPRX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | RPRX | discussed_in_filing Regulation | |
| topic_mention | RPRX | discussed_in_filing Healthcare & Bio | |
| topic_mention | RPRX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | RPRX | discussed_in_filing Cybersecurity | |
| topic_mention | RPRX | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001802768-26-000003 | EDGAR | 77K words |
| 2025-02-12 | 2024-12-31 | 0001802768-25-000010 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0001802768-24-000012 | EDGAR | — |
| 2023-02-15 | 2022-12-31 | 0001802768-23-000007 | EDGAR | — |
| 2022-02-15 | 2021-12-31 | 0001802768-22-000011 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001802768-21-000006 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001802768-25-000114 | EDGAR | 59K words |
| 2025-08-06 | 2025-06-30 | 0001802768-25-000095 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001802768-25-000027 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001802768-24-000058 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001802768-24-000045 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001802768-24-000021 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001802768-23-000029 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001802768-23-000023 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001802768-23-000015 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001802768-22-000045 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001802768-22-000035 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001802768-22-000020 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-11 | 0001802768-26-000002 | EDGAR | 7K words |
| 2025-12-22 | 0001193125-25-328759 | EDGAR | — |
| 2025-12-22 | 0001193125-25-328100 | EDGAR | — |
| 2025-11-05 | 0001802768-25-000113 | EDGAR | — |
| 2025-09-16 | 0001193125-25-204983 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179892 | EDGAR | — |
| 2025-08-06 | 0001193125-25-173988 | EDGAR | — |
| 2025-07-17 | 0001193125-25-160293 | EDGAR | — |
| 2025-05-19 | 0000950103-25-006186 | EDGAR | — |
| 2025-05-12 | 0001193125-25-117771 | EDGAR | — |
110 total filings indexed. 82 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001802768 |
| Ticker | RPRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report